Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study (Neurotherapeutics, (2022), 19, 4, (1248-1258), 10.1007/s13311-022-01237-4)

Michael Benatar; Joanne Wuu; Peter M. Andersen; Robert C. Bucelli; Jinsy A. Andrews; Markus Otto; Nita A. Farahany; Elizabeth A. Harrington; Weiping Chen; Adele A. Mitchell; Toby Ferguson; Sheena Chew; Liz Gedney; Sue Oakley; Jeong Heo; Sowmya Chary; Laura Fanning; Danielle Graham; Peng Sun; Yingying Liu; Janice Wong; Stephanie Fradette

doi:10.1007/s13311-022-01286-9

Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study (Neurotherapeutics, (2022), 19, 4, (1248-1258), 10.1007/s13311-022-01237-4)

Michael Benatar, Joanne Wuu, Peter M. Andersen, Robert C. Bucelli, Jinsy A. Andrews, Markus Otto, Nita A. Farahany, Elizabeth A. Harrington, Weiping Chen, Adele A. Mitchell, Toby Ferguson, Sheena Chew, Liz Gedney, Sue Oakley, Jeong Heo, Sowmya Chary, Laura Fanning, Danielle Graham, Peng Sun, Yingying LiuJanice Wong, Stephanie Fradette

Research output: Contribution to journal › Comment/debate

4 Scopus citations

Abstract

Due to an error during production, captions for Fig. 1, Fig. 5 and Fig. 6 in this article were formatted in a confusing manner in this article as originally published. The original article has been corrected.

Original language	English
Pages (from-to)	1686
Number of pages	1
Journal	Neurotherapeutics
Volume	19
Issue number	5
DOIs	https://doi.org/10.1007/s13311-022-01286-9
State	Published - Sep 2022

Access to Document

10.1007/s13311-022-01286-9

Fingerprint

Dive into the research topics of 'Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study (Neurotherapeutics, (2022), 19, 4, (1248-1258), 10.1007/s13311-022-01237-4)'. Together they form a unique fingerprint.

Cite this

Benatar, M., Wuu, J., Andersen, P. M., Bucelli, R. C., Andrews, J. A., Otto, M., Farahany, N. A., Harrington, E. A., Chen, W., Mitchell, A. A., Ferguson, T., Chew, S., Gedney, L., Oakley, S., Heo, J., Chary, S., Fanning, L., Graham, D., Sun, P., ... Fradette, S. (2022). Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study (Neurotherapeutics, (2022), 19, 4, (1248-1258), 10.1007/s13311-022-01237-4). Neurotherapeutics, 19(5), 1686. https://doi.org/10.1007/s13311-022-01286-9

@article{cf7a83ee45ff490b960c485755fd2349,

title = "Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study (Neurotherapeutics, (2022), 19, 4, (1248-1258), 10.1007/s13311-022-01237-4)",

abstract = "Due to an error during production, captions for Fig. 1, Fig. 5 and Fig. 6 in this article were formatted in a confusing manner in this article as originally published. The original article has been corrected.",

author = "Michael Benatar and Joanne Wuu and Andersen, {Peter M.} and Bucelli, {Robert C.} and Andrews, {Jinsy A.} and Markus Otto and Farahany, {Nita A.} and Harrington, {Elizabeth A.} and Weiping Chen and Mitchell, {Adele A.} and Toby Ferguson and Sheena Chew and Liz Gedney and Sue Oakley and Jeong Heo and Sowmya Chary and Laura Fanning and Danielle Graham and Peng Sun and Yingying Liu and Janice Wong and Stephanie Fradette",

note = "Publisher Copyright: {\textcopyright} The American Society for Experimental Neurotherapeutics, Inc. 2022.",

year = "2022",

month = sep,

doi = "10.1007/s13311-022-01286-9",

language = "English",

volume = "19",

pages = "1686",

journal = "Neurotherapeutics",

issn = "1933-7213",

number = "5",

}

Benatar, M, Wuu, J, Andersen, PM, Bucelli, RC, Andrews, JA, Otto, M, Farahany, NA, Harrington, EA, Chen, W, Mitchell, AA, Ferguson, T, Chew, S, Gedney, L, Oakley, S, Heo, J, Chary, S, Fanning, L, Graham, D, Sun, P, Liu, Y, Wong, J & Fradette, S 2022, 'Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study (Neurotherapeutics, (2022), 19, 4, (1248-1258), 10.1007/s13311-022-01237-4)', Neurotherapeutics, vol. 19, no. 5, pp. 1686. https://doi.org/10.1007/s13311-022-01286-9

Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study (Neurotherapeutics, (2022), 19, 4, (1248-1258), 10.1007/s13311-022-01237-4). / Benatar, Michael; Wuu, Joanne; Andersen, Peter M. et al.
In: Neurotherapeutics, Vol. 19, No. 5, 09.2022, p. 1686.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction to

T2 - Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study (Neurotherapeutics, (2022), 19, 4, (1248-1258), 10.1007/s13311-022-01237-4)

AU - Benatar, Michael

AU - Wuu, Joanne

AU - Andersen, Peter M.

AU - Bucelli, Robert C.

AU - Andrews, Jinsy A.

AU - Otto, Markus

AU - Farahany, Nita A.

AU - Harrington, Elizabeth A.

AU - Chen, Weiping

AU - Mitchell, Adele A.

AU - Ferguson, Toby

AU - Chew, Sheena

AU - Gedney, Liz

AU - Oakley, Sue

AU - Heo, Jeong

AU - Chary, Sowmya

AU - Fanning, Laura

AU - Graham, Danielle

AU - Sun, Peng

AU - Liu, Yingying

AU - Wong, Janice

AU - Fradette, Stephanie

PY - 2022/9

Y1 - 2022/9

N2 - Due to an error during production, captions for Fig. 1, Fig. 5 and Fig. 6 in this article were formatted in a confusing manner in this article as originally published. The original article has been corrected.

AB - Due to an error during production, captions for Fig. 1, Fig. 5 and Fig. 6 in this article were formatted in a confusing manner in this article as originally published. The original article has been corrected.

UR - http://www.scopus.com/inward/record.url?scp=85139177079&partnerID=8YFLogxK

U2 - 10.1007/s13311-022-01286-9

DO - 10.1007/s13311-022-01286-9

M3 - Comment/debate

C2 - 36175782

AN - SCOPUS:85139177079

SN - 1933-7213

VL - 19

SP - 1686

JO - Neurotherapeutics

JF - Neurotherapeutics

IS - 5

ER -

Benatar M, Wuu J, Andersen PM, Bucelli RC, Andrews JA, Otto M et al. Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study (Neurotherapeutics, (2022), 19, 4, (1248-1258), 10.1007/s13311-022-01237-4). Neurotherapeutics. 2022 Sep;19(5):1686. doi: 10.1007/s13311-022-01286-9

Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study (Neurotherapeutics, (2022), 19, 4, (1248-1258), 10.1007/s13311-022-01237-4)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this